Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period
The European Commission granted CMA in December 2021 for use of Nuvaxovid in individuals aged 18 and over, and Novavax filed for expanded CMA for use in adolescents aged 12 through 17 in March 2022
The partnership will further strengthen Olympus leadership in the diagnosis and staging of liver disease
According to the National Institutes of Health, more than six million Americans, most age 65 or older, may have dementia caused by Alzheimer's disease, a brain disorder known to slowly destroy memory and thinking skills
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
This surpasses the number of approvals supported in 2020
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
Subscribe To Our Newsletter & Stay Updated
